65 related articles for article (PubMed ID: 17278889)
1. FOLFOX-6 combination as the first-line treatment of locally advanced and/or metastatic pancreatic cancer.
Ghosn M; Farhat F; Kattan J; Younes F; Moukadem W; Nasr F; Chahine G
Am J Clin Oncol; 2007 Feb; 30(1):15-20. PubMed ID: 17278889
[TBL] [Abstract][Full Text] [Related]
2. [Efficacy and toxicity of FOLFOX6 regimen in treating colorectal cancer patients with liver metastasis].
Wang GQ; Wan DS; Zhou ZW; Pan ZZ; Chen G; Lu ZH; Fang YJ; Wu XJ; Li LR; Ding PR
Ai Zheng; 2007 Apr; 26(4):411-4. PubMed ID: 17430663
[TBL] [Abstract][Full Text] [Related]
3. FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study.
Zaanan A; Trouilloud I; Markoutsaki T; Gauthier M; Dupont-Gossart AC; Lecomte T; Aparicio T; Artru P; Thirot-Bidault A; Joubert F; Fanica D; Taieb J
BMC Cancer; 2014 Jun; 14():441. PubMed ID: 24929865
[TBL] [Abstract][Full Text] [Related]
4. Best supportive care (BSC) versus oxaliplatin, folinic acid and 5-fluorouracil (OFF) plus BSC in patients for second-line advanced pancreatic cancer: a phase III-study from the German CONKO-study group.
Pelzer U; Schwaner I; Stieler J; Adler M; Seraphin J; Dörken B; Riess H; Oettle H
Eur J Cancer; 2011 Jul; 47(11):1676-81. PubMed ID: 21565490
[TBL] [Abstract][Full Text] [Related]
5. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.
Burris HA; Moore MJ; Andersen J; Green MR; Rothenberg ML; Modiano MR; Cripps MC; Portenoy RK; Storniolo AM; Tarassoff P; Nelson R; Dorr FA; Stephens CD; Von Hoff DD
J Clin Oncol; 1997 Jun; 15(6):2403-13. PubMed ID: 9196156
[TBL] [Abstract][Full Text] [Related]
6. FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer.
Conroy T; Desseigne F; Ychou M; Bouché O; Guimbaud R; Bécouarn Y; Adenis A; Raoul JL; Gourgou-Bourgade S; de la Fouchardière C; Bennouna J; Bachet JB; Khemissa-Akouz F; Péré-Vergé D; Delbaldo C; Assenat E; Chauffert B; Michel P; Montoto-Grillot C; Ducreux M; ;
N Engl J Med; 2011 May; 364(19):1817-25. PubMed ID: 21561347
[TBL] [Abstract][Full Text] [Related]
7. Second-line oxaliplatin, folinic acid, and fluorouracil versus folinic acid and fluorouracil alone for gemcitabine-refractory pancreatic cancer: outcomes from the CONKO-003 trial.
Oettle H; Riess H; Stieler JM; Heil G; Schwaner I; Seraphin J; Görner M; Mölle M; Greten TF; Lakner V; Bischoff S; Sinn M; Dörken B; Pelzer U
J Clin Oncol; 2014 Aug; 32(23):2423-9. PubMed ID: 24982456
[TBL] [Abstract][Full Text] [Related]
8. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
Fine RL; Fogelman DR; Schreibman SM; Desai M; Sherman W; Strauss J; Guba S; Andrade R; Chabot J
Cancer Chemother Pharmacol; 2008 Jan; 61(1):167-75. PubMed ID: 17440727
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant modified FOLFOX-4 in patients with stage III rectum adenocarcinoma.
Cihan Ş; Uncu D; Babacan NA; Özdemir N; Odabaş H; Aksoy S; Öksüzoğlu B; Zengin N
Asian Pac J Cancer Prev; 2011; 12(4):967-70. PubMed ID: 21790235
[TBL] [Abstract][Full Text] [Related]
10. [FOLFOX regimen in the patients with locally advanced or metastatic gastric cancer].
Yan D; Dai H
Zhonghua Zhong Liu Za Zhi; 2009 Mar; 31(3):217-9. PubMed ID: 19615264
[TBL] [Abstract][Full Text] [Related]
11. Randomized Phase III Study of FOLFOX Alone or With Pegilodecakin as Second-Line Therapy in Patients With Metastatic Pancreatic Cancer That Progressed After Gemcitabine (SEQUOIA).
Hecht JR; Lonardi S; Bendell J; Sim HW; Macarulla T; Lopez CD; Van Cutsem E; Muñoz Martin AJ; Park JO; Greil R; Wang H; Hozak RR; Gueorguieva I; Lin Y; Rao S; Ryoo BY
J Clin Oncol; 2021 Apr; 39(10):1108-1118. PubMed ID: 33555926
[TBL] [Abstract][Full Text] [Related]
12. Alliance for clinical trials in oncology (ALLIANCE) trial A021501: preoperative extended chemotherapy vs. chemotherapy plus hypofractionated radiation therapy for borderline resectable adenocarcinoma of the head of the pancreas.
Katz MHG; Ou FS; Herman JM; Ahmad SA; Wolpin B; Marsh R; Behr S; Shi Q; Chuong M; Schwartz LH; Frankel W; Collisson E; Koay EJ; Hubbard JM; Leenstra JL; Meyerhardt J; O'Reilly E;
BMC Cancer; 2017 Jul; 17(1):505. PubMed ID: 28750659
[TBL] [Abstract][Full Text] [Related]
13. A randomised phase II study of modified FOLFIRI.3 vs modified FOLFOX as second-line therapy in patients with gemcitabine-refractory advanced pancreatic cancer.
Yoo C; Hwang JY; Kim JE; Kim TW; Lee JS; Park DH; Lee SS; Seo DW; Lee SK; Kim MH; Han DJ; Kim SC; Lee JL
Br J Cancer; 2009 Nov; 101(10):1658-63. PubMed ID: 19826418
[TBL] [Abstract][Full Text] [Related]
14. FOLFIRINOX after first-line gemcitabine-based chemotherapy in advanced pancreatic cancer: a retrospective comparison with FOLFOX and FOLFIRI schedules.
Foschini F; Napolitano F; Servetto A; Marciano R; Mozzillo E; Carratù AC; Santaniello A; De Placido P; Cascetta P; Butturini G; Frigerio I; Regi P; Silvestris N; Delcuratolo S; Vasile E; Vivaldi C; Bianco C; De Placido S; Formisano L; Bianco R
Ther Adv Med Oncol; 2020; 12():1758835920947970. PubMed ID: 33062062
[TBL] [Abstract][Full Text] [Related]
15. Liposomal irinotecan with fluorouracil and leucovorin after gemcitabine-based therapy in Japanese patients with metastatic pancreatic cancer: additional safety analysis of a randomized phase 2 trial.
Furuse J; Ueno M; Ikeda M; Okusaka T; Teng Z; Furuya M; Ioka T
Jpn J Clin Oncol; 2023 Jan; 53(2):130-137. PubMed ID: 36412114
[TBL] [Abstract][Full Text] [Related]
16. Chemotherapy toxicity and activity in patients with pancreatic ductal adenocarcinoma and germline BRCA1-2 pathogenic variants (gBRCA1-2pv): a multicenter survey.
Orsi G; Di Marco M; Cavaliere A; Niger M; Bozzarelli S; Giordano G; Noventa S; Rapposelli IG; Garajova I; Tortora G; Rodriquenz MG; Bittoni A; Penzo E; De Lorenzo S; Peretti U; Paratore C; Bernardini I; Mosconi S; Spallanzani A; Macchini M; Tamburini E; Bencardino K; Giommoni E; Scartozzi M; Forti L; Valente MM; Militello AM; Cascinu S; Milella M; Reni M
ESMO Open; 2021 Oct; 6(5):100238. PubMed ID: 34392104
[TBL] [Abstract][Full Text] [Related]
17. Phase II Study of 5-Fluorouracil, Oxaliplatin plus Dasatinib (FOLFOX-D) in First-Line Metastatic Pancreatic Adenocarcinoma.
George TJ; Ali A; Wang Y; Lee JH; Ivey AM; DeRemer D; Daily KC; Allegra CJ; Hughes SJ; Fan ZH; Cameron ME; Judge AR; Trevino JG
Oncologist; 2021 Oct; 26(10):825-e1674. PubMed ID: 34101295
[TBL] [Abstract][Full Text] [Related]
18. Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward.
Franck C; Müller C; Rosania R; Croner RS; Pech M; Venerito M
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32708493
[TBL] [Abstract][Full Text] [Related]
19. Reply to N. Fazio.
O'Reilly EM; Park W; Kelsen DP
J Clin Oncol; 2020 Jul; 38(21):2467-2468. PubMed ID: 32407214
[No Abstract] [Full Text] [Related]
20. Characteristics and survival of older patients with metastatic pancreatic cancer: a retrospective analysis of the AC Camargo Cancer Center experience.
Costa JG; de Jesus VHF; Camandaroba MPG; Dettino ALA
Ther Adv Med Oncol; 2019; 11():1758835919874650. PubMed ID: 31534492
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
